Similar articles

• Competitive dihydrofolate reductase binding assay of triazinate (NSC-139105), methasquin (NSC-122870), and aminopterin (NSC739).

  Myers CE, Eliot HM, Chabner BA. Myers CE, et al. Cancer Treat Rep. 1976 May;60(5):615-6. Cancer Treat Rep. 1976. PMID: 1033031 No abstract available.
• Identification of a reduced folate/methotrexate carrier in human KB-cells expressing high levels of membrane associated folate binding protein.

  Westerhof GR, Schornagel JH, Rijnboutt S, Pinedo HM, Jansen G. Westerhof GR, et al. Adv Exp Med Biol. 1993;338:771-4. doi: 10.1007/978-1-4615-2960-6_161. Adv Exp Med Biol. 1993. PMID: 8304226 No abstract available.
• Comparative studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell.

  Sirotnak FM, Donsbach RC. Sirotnak FM, et al. Cancer Res. 1972 Oct;32(10):2120-6. Cancer Res. 1972. PMID: 4404161 No abstract available.
• The molecular perspective: methotrexate.

  Goodsell DS. Goodsell DS. Stem Cells. 1999;17(5):314-5. doi: 10.1002/stem.170314. Stem Cells. 1999. PMID: 10527466 Review. No abstract available.
• Metabolism of the diaminoantifolates: biosynthesis and pharmacology of the 7-hydroxyl and polyglutamyl metabolites of methotrexate and related antifolates.

  Matherly LH, Seither RL, Goldman ID. Matherly LH, et al. Pharmacol Ther. 1987;35(1-2):27-56. doi: 10.1016/0163-7258(87)90104-5. Pharmacol Ther. 1987. PMID: 2447596 Review. No abstract available.